Clinical trial · Observational
Identify microRNAs in Cachexia in Pancreatic Carcinoma
Pilot Trial to Identify microRNAs in Cachexia in Patients With Pancreatic Carcinoma
NCT05275075CI-TRIAL-00113167SCC-miRPanCaterminatedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Translational scientist left university
Summary
Brief summary (as posted)
The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Resectable Pancreatic Adenocarcinoma | Pancreatic Adenocarcinoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Pancreatic cancer microRNA and messenger RNA expression. | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Pancreatic Cancer Cohort
- description
- All eligible adenocarcinoma pancreatic cancer patients with operable cancer.
- interventionNames
- Other: Pancreatic cancer microRNA and messenger RNA expression.
Primary outcomes (1)
- measure
- Proportion of African American pancreatic cancer patients with weight loss and cachexia.
- timeFrame
- 1 - 12 months
- description
- Evaluate weight loss and the markers of cachexia, albumin and psoas cross-sectional area, to see if African Americans with pancreatic cancer patients experience Grade I-IV cachexia at a higher frequency than other racial groups.
Secondary outcomes (2)
- measure
- Differences in microRNA and messenger RNA tumor expression profiles in all cancer patients undergoing pancreatic surgery.
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Male or female patient, who is ≥ 18 years old at the time of informed consent. 2. Patients with operable pancreatic tumors diagnosed in the last 12 months prior to consent with clinical discretion or pathology confirmed as adenocarcinoma. 3. Patient has stage I or higher disease who is considered a candidate for surgical resection of pancreatic cancer, with or without neoadjuvant chemotherapy. 4. Ability to provide written informed consent and HIPAA authorization. Exclusion Criteria: 1. Patients with pancreatic adenocarcinoma who do not meet the criteria for surgical resection. 2. Patient has cancer diagnosis other than primary pancreatic adenocarcinoma.
References
Publications (0)
Data not yet available
No reference posted for this study.